STOCK TITAN
  1. Home
  2. News
  3. JNJ

Johnson & Johnson Stock Price, News & Analysis

JNJ NYSE

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) drives global healthcare innovation through its pharmaceutical, medical technology, and consumer health divisions. This dedicated news hub provides investors and industry professionals with essential updates on regulatory developments, research breakthroughs, and strategic initiatives from one of healthcare's most diversified leaders.

Access real-time press releases and curated analysis covering FDA approvals, clinical trial results, and market expansion efforts. Our repository simplifies tracking JNJ's progress in oncology, immunology, and surgical advancements while maintaining perspective on its long-term corporate strategy.

Key updates include earnings disclosures, product pipeline milestones, and partnership announcements that demonstrate JNJ's commitment to addressing complex health challenges. Bookmark this page for streamlined access to verified information supporting informed decisions about this Dow Jones Industrial Average component.

News

FDA Panel Reiterates the Cancer Risks of Talc

Rhea-AI Summary

An FDA expert panel has called for new standards to ban talc use in consumer products including gum, candy, rice, and pharmaceuticals. The panel cited over 30 years of studies linking talc to ovarian cancer, which previously led Johnson & Johnson (JNJ) to discontinue its talc-based body powders. Dr. George Tidmarsh from Stanford University emphasized talc's carcinogenic nature, while Dr. Daniel Cramer's 1982 study showed an 82% increased risk of ovarian cancer in women regularly using talc-based powders. The National Institutes of Health and International Agency for Research on Cancer have recently upgraded talc's cancer risk classification from "possible" to "probable." Multiple tests, including FDA's own, have detected asbestos in cosmetic talc, further elevating cancer risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
fda approval
-
News

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference

Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) has announced its participation in Bernstein's 41st Annual Strategic Decisions Conference scheduled for May 28th, 2025. The company's management will engage in a Fireside Chat at 9:00 a.m. Eastern Time. Investors and interested parties can access a live audio webcast of the presentation through J&J's Investor Relations website. An archived version of the session will be made available approximately 48 hours after the webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
conferences
-
News

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) received a favorable vote (6-2) from the FDA's Oncologic Drugs Advisory Committee for DARZALEX FASPRO® in treating high-risk smoldering multiple myeloma (HR-SMM). Based on the Phase 3 AQUILA study, the treatment showed positive progression-free survival benefits. If approved, it would become the first approved treatment for HR-SMM, potentially preventing progression to active multiple myeloma. Currently, about 15% of newly diagnosed multiple myeloma cases are classified as smoldering, with 50% of HR-SMM patients likely to develop active disease within 2-3 years. The current standard of care is only active monitoring until progression. The FDA application was submitted in November 2024, and while the ODAC recommendation is non-binding, it represents a significant step toward potential approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
fda approval
News

Dean Omar Branham Shirley Recognized Twice Among ALM’s 2024 Top 100 Verdicts

Rhea-AI Summary
Dean Omar Branham Shirley secured two major verdicts against Johnson & Johnson (NYSE:JNJ) in 2024 over asbestos-contaminated talc-based Baby Powder cases. The firm's victories ranked among ALM's Top 100 Verdicts: a $260 million verdict in Oregon for Kyung Lee, a 49-year-old mother diagnosed with mesothelioma (#29), and a $63 million judgment in South Carolina for Michael Perry, a hospitality professional with terminal mesothelioma (#82). The Oregon case included $60M in compensatory and $200M in punitive damages, while the South Carolina verdict comprised $32.6M compensatory and $30.7M punitive damages. Both cases found JNJ liable for knowingly selling asbestos-contaminated products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
News

Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson’s Biosense Webster Medical Technology Unit

Rhea-AI Summary
A federal jury in Santa Ana, California has unanimously ruled against Johnson & Johnson's (NYSE: JNJ) Biosense Webster unit in favor of Innovative Health, resulting in a $147 million verdict. The jury found that Biosense Webster violated antitrust laws by withholding clinical support from hospitals using Innovative Health's FDA-regulated reprocessed catheters. The Association of Medical Device Reprocessors (AMDR) highlighted this as a victory for hospitals, providers, patients, and the environment. The case exposed anti-competitive practices in medical device reprocessing, where Original Equipment Manufacturers (OEMs) use various tactics to prevent hospitals from using reprocessed single-use devices (SUDs). AMDR provided detailed guidelines for hospitals to combat these practices, including documentation of threats, protection against unauthorized software updates, and rejection of contract clauses restricting reprocessing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
News

Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails

Rhea-AI Summary
Nachawati Law Group has filed three new lawsuits against Johnson & Johnson (NYSE: JNJ) on behalf of women who developed cancer from using talc-based products, following the dismissal of J&J's third bankruptcy attempt. The legal action resumes after years of delays caused by J&J's "Texas Two-Step" legal maneuvers. Over 50,000 women have alleged developing ovarian cancer from using Johnson's Baby Powder. U.S. Bankruptcy Judge Christopher Lopez rejected J&J's proposed settlement, citing issues with the claimants' voting process and improper attempts to shield non-debtor entities from future liability. The law firm represents thousands of women nationwide and plans to file more cases across different states to hold J&J accountable for what they claim are decades of corporate malfeasance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
News

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference scheduled for June 11th, 2025. The company's management will engage in a Fireside Chat session at 3:20 p.m. Eastern Time.

Investors and interested parties can access the live audio webcast through Johnson & Johnson's website at www.investor.jnj.com. A replay of the webcast will be made available approximately 48 hours after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
conferences
-
News

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) announced promising Phase 3 ICONIC-TOTALa trial results for icotrokinra (JNJ-2113), their first-in-class investigational targeted oral peptide for plaque psoriasis. The drug showed significant efficacy in treating high-impact skin sites, with 57% of patients achieving clear or almost clear skin compared to 6% on placebo at Week 16. Notably, 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieved site-specific clearance. The drug demonstrated particularly strong results in difficult-to-treat areas, with 42% of hand/foot psoriasis patients showing improvement. Importantly, icotrokinra maintained a favorable safety profile, with similar adverse event rates between treatment (50%) and placebo (42%) groups, and low serious adverse event rates (0.5% vs 1.9%).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
News

Johnson & Johnson expands efforts to champion the nursing workforce globally

Rhea-AI Summary
Johnson & Johnson (JNJ) has announced the expansion of its nursing workforce support through J&J CareCommunity, a new social impact platform. This initiative aims to address an expected global nursing shortfall of 4.5 million by 2030. Key programs include: - J&J Nurse Innovation Fellows program with UPenn Nursing and Wharton - Partnership with Aga Khan University training over 3,500 nurses in East Africa - Operation Smile's initiative training 2,880 nurses across 24 countries - WCEA collaboration providing 70 million training hours to nurses in 60+ countries - NurseHack4Health program engaging 5,500+ nurses globally - CofenPlay platform supporting 1+ million nurses in Brazil This expansion builds on J&J's 125+ year history of supporting nurses, including their $50 million Campaign for Nursing's Future which helped add one million nurses to the U.S. workforce.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
News

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) announced promising Phase 3 ASTRO study results for TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in ulcerative colitis (UC). At Week 24, TREMFYA® demonstrated significant improvements across all clinical and endoscopic measures. The drug achieved clinical remission rates of 35.3% (100mg q8w) and 36.4% (200mg q4w) compared to 9.4% for placebo. Endoscopic improvement was observed in 40.3% (100mg q8w) and 45.0% (200mg q4w) of patients versus 12.2% for placebo. TREMFYA® is positioned to become the first and only IL-23 inhibitor offering both SC and IV induction options for UC treatment. The drug showed efficacy in both biologic/JAK inhibitor-naïve and refractory patients, with a safety profile consistent with previous findings. A supplemental Biologics License Application (sBLA) was submitted to the FDA in November 2024 for SC induction approval in UC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $205.75 as of January 8, 2026.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 499.9B.
Stock JNJ logo
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

#19 Ranked by Market Cap
#1243 Ranked by Dividends

JNJ Stock Data

499.90B
2.41B
0.06%
74.37%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK